Genmab A/S (GMAB) on Decifer

Decifer ranks GMAB number 190 of 276 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 9% and it turns most of its profit into real cash.
• Revenue is expected to grow about 18% a year, profits are expected to grow 48%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Revenue expected to grow about 18% a year with profits expected to grow 48% in a leading healthcare sector are healthy, but no stated reason to grow and momentum of 7 out of 35 keep it modest.

The current read

The evidence on GMAB lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Genmab A/S operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Read the full GMAB research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.